RHEUMATOID ARTHRITIS

The Crescendo Bioscience Outcome Study compares Vectra DA VECTRA

The Crescendo Bioscience Outcome Study compares Vectra DA guided-care to usual care for rheumatoid arthritis (RA) patients with inadequate response to methotrexate. To qualify for this study, you must:

• Be between the ages of 18 and 80 years old

• Have received weekly methotrexate (MTX) treatment for at least 3 months

• Have at least 3 swollen and 3 tender joints

• Additional criteria may apply

-care to usual care for rheumatoid arthritis (RA) patients with inadequate response to methotrexate. To qualify for this study, you must:

• Be between the ages of 18 and 80 years old

• Have received weekly methotrexate (MTX) treatment for at least 3 months

• Have at least 3 swollen and 3 tender joints

• Additional criteria may apply